Organigram Global Inc. (TSX:OGI)
Canada · Delayed Price · Currency is CAD | Market Cap | 203.05M -38.0% |
| Revenue (ttm) | 309.18M +38.1% |
| Net Income | 86.62M +1,014.5% |
| EPS | 0.64 +821.8% |
| Shares Out | 141.01M |
| PE Ratio | 2.27 |
| Forward PE | 18.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 160,833 |
| Open | 1.490 |
| Previous Close | 1.490 |
| Day's Range | 1.430 - 1.500 |
| 52-Week Range | 1.195 - 3.090 |
| Beta | 1.91 |
| Analysts | Buy |
| Price Target | 3.12 (+113.7%) |
| Earnings Date | Dec 15, 2026 |
About Organigram Global
Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates; and adult use recreational cannabis under the SHRED, Big Bag O’ Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Boxhot, Edison JOLTS, Wola, Rizzlers, DEBUNK, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings and dr... [Read more]
Full Company ProfileFinancial Performance
In fiscal year 2025, Organigram Global's revenue was 259.18 million, an increase of 62.15% compared to the previous year's 159.84 million. Losses were -24.76 million, -45.51% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for OGI stock is "Buy." The 12-month stock price target is $3.12, which is an increase of 113.70% from the latest price.
News
Organigram Global to Host 2026 OG Investor Session
TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (the "Company" or "Organigram"), Canada's #1 cannabis company by market share and a growing global cannabis platform, today an...
Organigram Global Accelerates Integration of Sanity Group Under Unified Global Operating Structure
TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (“Organigram” or the “Company”) today announced an important milestone in its global growth strategy through the accelerated i...
Organigram (OGI) Q3 2026 Earnings Call Transcript
Revenue jumped 49% to $105.8 million on Sanity acquisition.
Organigram Global Q3 Earnings Call Highlights
Organigram Global NASDAQ: OGI reported record third-quarter fiscal 2026 revenue and adjusted EBITDA, aided by the consolidation of Germany-based Sanity Group and improving performance in several Canad...
Organigram Global Earnings Call Transcript: Q3 2026
Record quarterly revenue and adjusted EBITDA were achieved, driven by the Sanity Group acquisition and strong Canadian operations. International revenue now exceeds one-third of total revenue, with robust growth in flower, vapes, and beverages. Margin expansion and positive Q4 free cash flow are expected.
Organigram Global Earnings release: Q3 2026
Organigram Global released its Q3 2026 earnings on August 11, 2026, summarizing the period's financial results.
Organigram Global Registration statement: Q3 2026
Organigram Global filed a registration statement on August 11, 2026, providing details about a securities offering with the SEC.
Organigram Global Registration statement: Q3 2026
Organigram Global filed a registration statement on August 11, 2026, providing details about a securities offering with the SEC.
Organigram Global Slides: Q3 2026
Organigram Global has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on August 11, 2026.
OGI Looks 44.6% Undervalued on GF Value™ Amid Price-to-Sales Caution
OGI Looks 44.6% Undervalued on GF Value™ Amid Price-to-Sales Caution
Organigram reports Q3 net revenue $105.78M vs. $70.79M last year
Reports Q3 adjusted EBITDA $13.4M vs. $5.69M last year. “This quarter marks an important milestone for Organigram (OGI) as we report the first quarter of financial contributions from Sanity Group,…
Organigram Reports Record Third Quarter Fiscal 2026 Results
TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share2 and a growing global cannabis platform followi...
Organigram to Report Third Quarter Fiscal 2026 Results on August 11, 2026
TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share and a growing global cannabis platform followin...
Organigram Provides Business Update Highlighting Initial Sanity Performance and Canadian Market Share
TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share and a growing global cannabis platform followin...
Organigram Global Q2 Earnings Call Highlights
Organigram Global NASDAQ: OGI reported a weaker second quarter for fiscal 2026, with management attributing the decline to operational issues in key product categories, softer Canadian cannabis market...
Organigram Global Earnings Call Transcript: Q2 2026
Q2 fiscal 2026 saw revenue and margin declines due to operational issues and market softness, but remediation efforts and the Sanity Group acquisition are expected to drive stronger performance in the second half. Guidance for fiscal 2026 projects net revenue above CAD 350 million and improved profitability.
Organigram Global Earnings release: Q2 2026
Organigram Global released its Q2 2026 earnings on May 12, 2026, summarizing the period's financial results.
Organigram Global Registration statement: Q2 2026
Organigram Global filed a registration statement on May 12, 2026, providing details about a securities offering with the SEC.
Organigram Global Registration statement: Q2 2026
Organigram Global filed a registration statement on May 12, 2026, providing details about a securities offering with the SEC.
Organigram Global Slides: Q2 2026
Organigram Global has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on May 12, 2026.
OGI Reports Q2 Financials with Adjusted EBITDA Decline
OGI Reports Q2 Financials with Adjusted EBITDA Decline
OGI Forecasts Strong FY26 Adjusted EBITDA and Low Capital Expenditures
OGI Forecasts Strong FY26 Adjusted EBITDA and Low Capital Expenditures
Options Volatility and Implied Earnings Moves Today, May 12, 2026
Today, several major companies are expected to report earnings: Lineage Therap (LCTX), Achieve Life Sciences (ACHV), Zebra Tech (ZBRA), Organigram Global (OGI), Lithium Argentina (LAR), GrowGeneration...
Organigram Reports Second Quarter Fiscal 2026 Results
TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share1, is pleased to announce its results for the se...
Organigram (OGI) Set to Release Q2 FY2026 Earnings Report
Organigram (OGI) Set to Release Q2 FY2026 Earnings Report